Immunization, Not Vaccination: Monoclonal Antibodies for Infant RSV Prevention and the US Vaccines for Children Program
- JP Sevilla
Access Resources
About
This commentary article is about using monoclonal antibodies, like nirsevimab, to protect infants from RSV. It describes how RSV affects many babies and can lead to hospital visits. Currently, only a small group of high-risk infants get protection through existing treatments. The author argues that all infants should have access to these new antibodies through the Vaccines for Children program. Although traditionally focused on vaccines providing active immunity, the author believes passive immunization products like nirsevimab should be included because they offer similar health benefits and could help more children stay healthy without being excluded just because they're not traditional vaccines.
Tags
More like this
The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.